Factor XIII

Human blood coagulation Factor XIII B subunit


(hFXIII B, recombinantly produced in insect cells)

Order
Quantity
Price
Status
200 µg 370 € available


Documents
Art. No. T050
Synonym Recombinant Fibrin stabilizing factor B subunit

recombinant Factor XIII B subunit T050 by Zedira
Molecular Weight 80 kDa (monomer)
Source Recombinantly produced in insect cells
Purity > 95% [by SDS-PAGE]
Appearance White lyophilized solid.
Description Recombinant human Factor XIII B subunit is a carrier protein for blood coagulation Factor XIII A subunit. Factor XIII B subunit is a typical mosaic protein and consists of 10 tandem repeats, called “sushi”-domains. Its function is to protect Factor XIII A subunit from slow spontaneous activation and clearance.
Reagents The recombinant human Factor XIII B subunit is lyophilized from 20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA.
Reconstitution Add the volume of H2O the protein is lyophilized from (see Certificate of Analysis) to the vial of lyophilized powder. Rotate vial gently until solid dissolves. After reconstitution the solution should be stored frozen in working aliquots. Keep cooled on ice for short term storage.
Application Factor XIII B subunit is a carrier protein. The recombinantly expressed protein is able to form a heterotetrameric complex with recombinant Factor XIII A from human, as well as the analogous proteins from pig, dog, mouse, and rat as shown by native PAGE below (Heil et al., 2013). Accordingly, the protein may be used for biochemical studies understanding the physiological function of FXIII, for example determination of the binding constant between Factor XIII A and B subunit (Katona et al., 2014).
Storage Storage for several months is possible at > - 20°C.
Delivery is possible at ambient temperature
Reference(s) Böhm et al., J. Med. Chem. 2014, 57:10355-65
Heil et al., Thromb. Res., 2013, 131, e214–e22
Katona et al., Blood, 2014, 123, 1757-63
Note INTENDED FOR RESEARCH USE ONLY, NOT FOR USE IN HUMAN, THERAPEUTIC OR DIAGNOSTIC APPLICATIONS.

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy

  • Gordon Research Conference: Transglutaminases in Human Disease Processes

    12.06.2022 - 17.06.2022
    Mount Snow, USA